Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLB | P06746 | 2/20 | 0.34 |
| ▸ | MEN1 | O00255 | 1/20 | 0.34 |
| ▸ | USP2 | O75604 | 1/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.34 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.33 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.32 |
| ▸ | NPC1 | O15118 | 1/20 | 0.31 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.30 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.30 |
| ▸ | TRPM8 | Q7Z2W7 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13470535 | 1.00 | POLB (0.34) | POLBMEN1USP2KMT2AHSD17B10 | |
| SCHEMBL13470609 | 0.92 | POLB (0.34) | POLBMEN1USP2KMT2AHSD17B10 | |
| SCHEMBL13470531 | 0.90 | ABCB1 (0.34) | POLBMEN1USP2KMT2AHSD17B10 | |
| SCHEMBL16214806 | 0.88 | MEN1 (0.31) | POLBMEN1USP2KMT2A | |
| SCHEMBL13454860 | 0.81 | TRPM8 (0.35) | POLBMEN1USP2KMT2AHSD17B10 | |
| SCHEMBL21099786 | 0.81 | POLB (0.35) | POLBMEN1USP2KMT2AHSD17B10 | |
| SCHEMBL16730063 | 0.80 | POLB (0.49) | POLBMEN1USP2KMT2AHSD17B10 | |
| SCHEMBL17968546 | 0.80 | POLB (0.49) | POLBMEN1USP2KMT2AHSD17B10 | |
| SCHEMBL30002440 | 0.80 | POLB (0.49) | POLBMEN1USP2KMT2AHSD17B10 | |
| SCHEMBL21099791 | 0.80 | POLB (0.35) | POLBMEN1USP2KMT2AHSD17B10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2697241-B1 | 1'-SUBSTITUTED PYRIMIDINE N-NUCLEOSIDE ANALOGS FOR ANTIVIRAL TREATMENT | GILEAD SCIENCES INC (US) | 2019-06-12 | — | — | EP | disclosed |
| US-8877733-B2 | 1′-substituted pyrimidine N-nucleoside analogs for antiviral treatment | GILEAD SCIENCES, INC. (US) | 2014-11-04 | — | — | US | disclosed |
| US-20120263678-A1 | 1'-SUBSTITUTED PYRIMIDINE N-NUCLEOSIDE ANALOGS FOR ANTIVIRAL TREATMENT | GILEAD SCIENCES, INC. (US) | 2012-10-18 | — | — | US | disclosed |
| WO-2012142523-A2 | 1'-SUBSTITUTED PYRIMIDINE N-NUCLEOSIDE ANALOGS FOR ANTIVIRAL TREATMENT | GILEAD SCIENCES, INC. (US) | 2012-10-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120263678-A1 | 1'-SUBSTITUTED PYRIMIDINE N-NUCLEOSIDE ANALOGS FOR ANTIVIRAL TREATMENT | PNP, NUDT1, TYMP | POLB 545/4885MEN1 3685/4885USP2 4316/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.